ClinicalTrials.gg
Active, not recruitingNCT05095727Updated Dec 15, 2025

A Study of mRNA-3745 in Adult and Pediatric Participants With Glycogen Storage Disease Type 1a (GSD1a)

A Phase 1/2 interventional study of mRNA-3745 in Glycogen Storage Disease, sponsored by ModernaTX, Inc.. Active, not recruiting at 16 sites in 6 countries. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2025-12-15.

Sponsored by ModernaTX, Inc. (part of Moderna, Inc.) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
15
Allocation
Non-randomized
Ages
6 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 16 studies in Glycogen Storage Disease with a site in United States — 5 open to participants now, 6 under way, none of them phase 3. Glycogen Storage Disease · United States.

Started
2022
the only one that year
Phase 1/2
5 of 16
2 open now
Registered
12th of 16
by date
Lead sponsor
1 of 16
ModernaTX, Inc.

Among the 16 studies in Glycogen Storage Disease with a site in United States, this one is the only one that started in 2022, is one of 5 in phase 1/2, and was the 12th registered.

Glycogen Storage Disease

36 studies on the registry are indexed under Glycogen Storage Disease; 13 are open to participants now.

Browse Glycogen Storage Disease studies →

Open to participants now

5 of the 16 studies in Glycogen Storage Disease with a site in United States are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 9 Glycogen Storage Disease studies recruiting now, 4 set no upper age limit and 4 stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.

This study: 6 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Glycogen Storage Disease with a site in United States, or all of them as a file.
02

Study summary

The main goal of this trial is to evaluate the safety and tolerability of mRNA-3745 via intravenous (IV) administration in adult and pediatric participants with GSD1a.

Read the detailed description

The study includes a single ascending dose (SAD) stage and a multiple ascending dose (MAD) stage. Participants enrolled in the MAD stage have the option to continue treatment in an open-label extension (OLE) period that will assess long-term safety and clinical activity of mRNA-3745.

03

Conditions studied

  • Glycogen Storage Disease

Keywords

  • Glycogen storage disease type 1a
  • GSD1a
  • Von Gierke disease
  • Glucose metabolism disorder
  • Genetic disorder
  • Autosomal recessive disorder
  • messenger RNA
  • mRNA
  • Pediatric
04

Who can participate

Ages eligible
6 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented GSD1a with confirmation of biallelic gene encoding glucose-6-phosphatase-α (G6PC) mutations by genetic testing.
  • Absence of hospitalization for hypoglycemia in the 4 weeks prior to Screening

Exclusion criteria

Exclusion Criteria:

  • Solid organ transplant
  • Received gene therapy for GSD1a
  • Presence of liver adenoma >5 centimeters (cm) in size
  • Diagnosis of type 1 or type 2 diabetes mellitus
  • Presence of liver adenoma with growth of >2 cm or >5 newly diagnosed liver adenomas, in the previous 2 years

Note: Additional inclusion/exclusion criteria may apply, per protocol.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    SAD: mRNA-3745

    Participants will receive a single intravenous (IV) dose of mRNA-3745 on Day 1 in an inpatient setting. Participants that are/have been enrolled in the study and receive an administration of mRNA-3745 may also enroll in one of the MAD cohorts. The first MAD dose must occur at least 21 days after the SAD dose.

    Drug: mRNA-3745

  • Experimental
    MAD: mRNA-3745

    Participants will receive multiple IV doses of mRNA-3745 in an inpatient setting. Participants will have the option to continue treatment in the OLE.

    Drug: mRNA-3745

Interventions

  • DrugmRNA-3745

    Sterile frozen liquid dispersion for injection

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and TEAEs Leading to Treatment Discontinuation

    Time frame: Day 1 up to approximately 3.5 years

Secondary outcomes

  1. Number of Participants Not Experiencing Hypoglycemia During Fasting Challenges

    Hypoglycemia is defined as blood glucose \<60 milligrams (mg)/deciliter (dL) (3.3 millimoles \[mmol\]/liter \[L\]) and/or symptoms of hypoglycemia.

    Time frame: Baseline through up to Week 32

  2. Change From Baseline of Area Under the Effect Curve (AUEC) of Blood Glucose and Lactate During Fasting Challenges

    Time frame: Baseline through up to Week 32

  3. Change From Baseline in Time to Hypoglycemia During Fasting Challenges

    Time frame: Baseline through up to Week 32

  4. Change From Baseline in Maximum Effect (Emax) During Fasting Challenges

    Time frame: Baseline through up to Week 32

  5. SAD only: Maximum Observed Concentration (Cmax) of Messenger Ribonucleic Acid (mRNA) and Lipid Nanoparticle (LNP)

    Time frame: Pre-infusion, during infusion, at the end of infusion (EOI) and post-infusion on Day 1 up to Week 52

  6. SAD only: Area Under the Concentration-Time Curve From Time 0 to the Time of the Last Measurable Concentration (AUC0-t) of mRNA and LNP

    Time frame: Pre-infusion, during infusion, at EOI and post-infusion on Day 1 up to Week 52

  7. Change From Baseline in Metabolic Biomarkers of GSD1a

    Time frame: Baseline through up to approximately 6.5 years

  8. MAD only: Maximum Observed Concentration at Steady State (Cmax,ss) of mRNA and LNP

    Time frame: Pre-infusion, during infusion, at the EOI and post-infusion on Day 1 up to Week 52

07

Study locations

16 sites
08

References and documents

Publications

  • Cao J, Choi M, Guadagnin E, Soty M, Silva M, Verzieux V, Weisser E, Markel A, Zhuo J, Liang S, Yin L, Frassetto A, Graham AR, Burke K, Ketova T, Mihai C, Zalinger Z, Levy B, Besin G, Wolfrom M, Tran B, Tunkey C, Owen E, Sarkis J, Dousis A, Presnyak V, Pepin C, Zheng W, Ci L, Hard M, Miracco E, Rice L, Nguyen V, Zimmer M, Rajarajacholan U, Finn PF, Mithieux G, Rajas F, Martini PGV, Giangrande PH. mRNA therapy restores euglycemia and prevents liver tumors in murine model of glycogen storage disease. Nat Commun. 2021 May 25;12(1):3090. doi: 10.1038/s41467-021-23318-2. PubMed 34035281 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2022 (actual). Primary completion is estimated for Nov 2026, 53 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2021
First posted
Oct 27, 2021
StartActual
Jun 1, 2022
Primary completionEst.
Nov 30, 2026
CompletionEst.
Nov 30, 2026
Last update
Dec 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05095727
Lead sponsor
ModernaTX, Inc.
Responsible party
Sponsor
First posted
Oct 27, 2021
Start date
Jun 1, 2022
Primary completion
Nov 30, 2026 (estimated)
Completion
Nov 30, 2026 (estimated)
Last update
Dec 15, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion